Results 101 to 110 of about 91,870 (284)

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [PDF]

open access: yes, 2017
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
Abdallah, K.   +80 more
core   +2 more sources

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang   +7 more
wiley   +1 more source

Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice [PDF]

open access: yes, 2009
The SpAs are a group of overlapping, chronic, inflammatory rheumatic diseases including AS, a chronic inflammatory disease primarily affecting the SI joints.
Elewaut, Dirk, Matucci-Cerinic, Marco
core   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler   +4 more
wiley   +1 more source

Long-Term Corticosteroid-Sparing Immunosuppression for Cardiac Sarcoidosis. [PDF]

open access: yes, 2019
Background Long-term corticosteroid therapy is the standard of care for treatment of cardiac sarcoidosis (CS). The efficacy of long-term corticosteroid-sparing immunosuppression in CS is unknown.
Benn, Bryan S   +17 more
core  

Disease and psychological status in ankylosing spondylitis. [PDF]

open access: yes, 2006
Objectives. Psychological factors may be important in the assessment and management of ankylosing spondylitis (AS). Our primary objective was to describe associations between disease and psychological status in AS, using AS-specific assessment tools and ...
Goodacre, J. A.   +5 more
core   +1 more source

Beyond Gut Modulation: A Critical Review of the Therapeutic Potential, Safety, and Clinical Prospects of Natural Polysaccharides for IBD

open access: yesFood Safety and Health, EarlyView.
In this review, we critically summarized the application of natural polysaccharides (NPs) for the treatment of IBD. This approach combines, in a unique way (right), the basic structure–activity relationships of NPs from different origins (left) with their multipronged mode of action, which involves modulation of the gut microbiota and other ...
Felix Danso   +3 more
wiley   +1 more source

Outcomes of a National Cohort of Children with Acute Severe Ulcerative Colitis

open access: yesFrontiers in Pediatrics, 2018
AimAll Irish children with ulcerative colitis (UC) attend the National Centre for Paediatric Gastroenterology at Our Lady’s Children’s Hospital, Crumlin. The aim of this study was to determine the outcomes of children with acute severe ulcerative colitis
Abisoye O. Akintimehin   +7 more
doaj   +1 more source

Clinical performance of an infliximab rapid quantification assay [PDF]

open access: yes, 2017
Background: Therapeutic drug monitoring (TDM)-based algorithms can be used to guide infliximab (IFX) adjustments in inflammatory bowel disease (IBD) patients.
Afonso, Joana   +21 more
core   +2 more sources

Long term treatment with infliximab in pediatric Vogt-Koyanagi-Harada disease

open access: yesAmerican Journal of Ophthalmology Case Reports, 2018
Purpose: To report a case of pediatric Vogt-Koyanagi-Harada (VKH) successfully treated with infliximab and methotrexate for ten years. Observations: A 9-year-old Hispanic girl with VKH disease, was successfully treated with oral methotrexate 15 mg/week ...
Gustavo A. Budmann   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy